TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1588379
Drug: AG (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG (250 mg AG twice a day)
Study: 3838405
Drug: Molsidomine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (4 mg, sublingually administered)
Study: 3838405
Drug: Placebo (sublingually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sublingually administered)
Study: 30658621
Drug: Group Acceptance
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Acceptance and Commitment Therapy (ACT) intervention delivered over 7 weeks
Study: 22730105
Drug: Olanzapine monotherapy
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine monotherapy (flexible-dose for 8 weeks)
Study: 10483607
Drug: 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 calcium folinate
Study: 10483607
Drug: 100 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2 calcium folinate
Study: 10483607
Drug: 650 mg/m2/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg/m2/d fluorouracil
Study: 8724043
Drug: Liposomal daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal daunorubicin 40 mg/m2 every 2 weeks for 12 weeks
Study: 1929343
Drug: Single-dose amoxicillin-clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose amoxicillin-clavulanate combination
Study: 1929343
Drug: 3-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day regimen of amoxicillin-clavulanate
Study: 30746581
Drug: Yisaipu® tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yisaipu® tapering (50 mg every other week from week 13 to week 24)
Study: 30746581
Drug: Full-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose therapy (50 mg/week for the entire study duration)
Study: 28371248
Drug: Targeted group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted group administered antibiotics based on bile culture results
Study: 28371248
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group administered cefmetazole
Study: 26410119
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy (VRET) with social interactions; two exposure sessions
Study: 15256675
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor therapy (perindopril, 4 mg daily)
Study: 11778855
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide whitening solution
Study: 9402352
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg q.d. for 6 weeks)
Study: 9402352
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg q.d. for 6 weeks) with amoxicillin (500 mg t.i.d.) and metronidazole (500 mg b.i.d.) for the first 12 days
Study: 9402352
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (120 mg q.i.d. for 6 weeks) with amoxicillin and metronidazole (at same dosages as in group B)
Study: 9402352
Drug: Ranitidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine with amoxicillin and metronidazole (group B)
Study: 9402352
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate with amoxicillin and metronidazole (group C)
Study: 3036903
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg DEX, iv, 45-60 min before sternotomy, enflurane anesthesia
Study: 31728664
Drug: Drospirenone 4
Normalized name: drospirenone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 4 mg (DRSP)
Study: 31728664
Drug: Desogestrel 0.075
Normalized name: desogestrel 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel 0.075 mg (DSG)
Study: 9715220
Drug: Availability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Availability of intravenous catheters
Study: 7912442
Drug: Both light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both light treatment conditions
Study: 2660552
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g twice daily
Study: 24899597
Drug: 7.5% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% CO2 inhalation
Study: 22733833
Drug: Dabigatran (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (150 mg twice a day, switching to 110 mg twice a day at age 80)
Study: 16822563
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg daily for 6 months)
Study: 16822563
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg daily for 6 months)
Study: 15164111
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk consumption >500 g/day
Study: 15164111
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk consumption <500 g/day
Study: 8308770
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drug (NSAID) therapy
Study: 2962333
Drug: Nebulised ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised ipratropium bromide 0.05 mg
Study: 2962333
Drug: Nebulised ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised ipratropium bromide 0.5 mg
Study: 2962333
Drug: Salbutamol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.25 mg
Study: 2962333
Drug: Salbutamol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 2.5 mg
Study: 20399986
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/d plus telmisartan 80 mg/d (RT group)
Study: 20399986
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/d plus irbesartan 300 mg/d (RI group)
Study: 20399986
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/d plus olmesartan 20 mg/d (RO group)
Study: 25271389
Drug: Parenteral nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutritional support
Study: 8844448
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg three times daily for 9 days)
Study: 6406586
Drug: Nitroglycerin (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (acute therapy)
Study: 6406586
Drug: Nitroglycerin (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (sustained therapy)
Study: 31201876
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine as needed
Study: 31201876
Drug: Titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of morphine
Study: 31201876
Drug: Titrate baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrate baseline oxycodone
Study: 31201876
Drug: Stepwise switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise switch to morphine
Study: 31201876
Drug: Add morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add morphine on baseline oxycodone
Study: 31201876
Drug: Add morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add morphine on baseline fentanyl
Study: 20111849
Drug: Intramuscular botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular botulinum toxin‐A (Dysport 500‐1000U)
Study: 15692475
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (200 mg once weekly, 5 40‐mg tablets)
Study: 10649166
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (1 g/kg body weight) for 2 consecutive days each month until 36 weeks' gestation
Study: 9153784
Drug: Methanol administered
Normalized name: methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methanol administered orally at a dose of 10 mg/kg
Study: 9153784
Drug: Methanol administered
Normalized name: methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methanol administered intravenously at a dose of 10 mg/kg
Study: 8475628
Drug: Hypokinesia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypokinesia with daily fluid and salt supplements (water 26 ml/kg body weight and sodium chloride 0.16 g/kg body weight)
Study: 3895186
Drug: Carotenoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid treatment (100 mg daily of betacarotene and canthaxanthine)
Study: 3895186
Drug: Oxychloroquine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxychloroquine treatment (200 mg daily)
Study: 8327167
Drug: Propofol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (intravenous anesthetic)
Study: 12972520
Drug: Exisulind 125
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind 125 mg orally bid in combination with capecitabine 2,000 mg/m2 for 14 days in 21-day cycles
Study: 12972520
Drug: Exisulind 125
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind 125 mg orally bid
Study: 8840343
Drug: Amitriptyline 30
Normalized name: amitriptyline 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 30 mg/day
Study: 8840343
Drug: Flupentixole 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixole 1.5 mg/day
Study: 8840343
Drug: Clotiazepam 15
Normalized name: clotiazepam
DrugBank: Clotiazepam (DB01559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotiazepam 15 mg/day
Study: 8840343
Drug: Meta-analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analysis of all agents
Study: 1634784
Drug: Diazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.1 mg/kg) followed by placebo (0.5 mg/kg as bolus and 0.5 mg/kg/hour infusion)
Study: 1634784
Drug: Diazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.1 mg/kg) followed by ketamine (0.5 mg/kg as bolus and 0.5 mg/kg/hour infusion)
Study: 30424786
Drug: GSK1120360A (prolyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1120360A (prolyl hydroxylase inhibitor)
Study: 30424786
Drug: Daprodustat (clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat (clinical prolyl hydroxylase inhibitor)
Study: 25448495
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) administered 1 hour before surgery
Study: 19844694
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg fish oil (FO) 1 day before LPS
Study: 19844694
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg fish oil (FO) 1 day before LPS
Study: 19844694
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg fish oil (FO) 2 hours before LPS
Study: 14704377
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (case managers with risk and benefit information)
Study: 10546917
Drug: LI160 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI160 (900 mg/d)
Study: 8914412
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (fluticasone propionate; Flunase) and antiallergic medicine (azelastin) administered 4 weeks before pollen season (Group A)
Study: 8914412
Drug: Antiallergic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiallergic medicine (azelastin) administered at the same time as Group A, with topical corticosteroid given after symptoms appeared (Group B)
Study: 8914412
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (fluticasone propionate; Flunase) in Group A
Study: 1854375
Drug: Alcohol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.25 g/kg‐1 g/kg)
Study: 6587183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgery and adjuvant chemotherapy
Study: 26920949
Drug: Acotiamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide (300 mg/day) and rabeprazole (10 mg/day) combination therapy
Study: 26920949
Drug: Acotiamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide (300 mg/day)
Study: 22721612
Drug: Intravenous glutamate
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous glutamate infusion
Study: 14586388
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine
Study: 14586388
Drug: Intravenous methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methamphetamine
Study: 30569083
Drug: Pimavanserin 34
Normalized name: pimavanserin 34 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin 34 mg daily for 12 weeks
Study: 25459391
Drug: Gemcitabine 1000mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000mg/m² plus trastuzumab (8mg/kg loading dose, then 6 mg/kg every 21 days)
Study: 23489705
Drug: Pidotimod 400
Normalized name: pidotimod 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 400 mg, administered orally once a day for 90 days
Study: 19189986
Drug: Ketamine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.2 mg kg(‐1)
Study: 15639698
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% cream QD for 12 weeks
Study: 15639698
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream QD for 12 weeks
Study: 12370877
Drug: Therapeutic combinations
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic combinations (B1: hot pack plus active ROM; B2: B1 plus ischemic compression; B3: B2 plus TENS; B4: B1 plus stretch with spray; B5: B4 plus TENS; B6: B1 plus interferential current and myofascial release)
Study: 9440585
Drug: Heparin bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bonding
Study: 31777236
Drug: Estazolam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam (oral tablets once a day for 4 weeks)
Study: 27130075
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment regimens (biphasic, aspart, detemir) in addition to metformin or placebo
Study: 27130075
Drug: Weight gain
Normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight gain during the first 3 months of the trial and subsequent dose of insulin
Study: 25468411
Drug: Capsaicin capsules
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin capsules
Study: 23308016
Drug: Losartan, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, 100 mg (n=77)
Study: 18097505
Drug: G. lucidum
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. lucidum extract (6 mg once a day)
Study: 17038636
Drug: AHA step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AHA step 1 diet plus simvastatin (40 mg/d)
Study: 9210109
Drug: Computer reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer reading treatment
Study: 29346040
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (observation)
Study: 29275607
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.5 mg/kg in 250 ml of 0.9% normal saline for 1 hour daily for 7 days)
Study: 29275607
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.9% normal saline infusion)
Study: 25010823
Drug: HME1L (Heat
Approvals — FDA: no, EMA: no, PMDA: no
Description: HME1L (Heat and Moisture Exchanger with low fresh gas flow 1 L·min)
Study: 25010823
Drug: HME3L (Heat
Approvals — FDA: no, EMA: no, PMDA: no
Description: HME3L (Heat and Moisture Exchanger with high fresh gas flow 3 L·min)
Study: 25010823
Drug: 1L (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1L (No Heat and Moisture Exchanger with low fresh gas flow 1 L·min)
Study: 25010823
Drug: 3L (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3L (No Heat and Moisture Exchanger with high fresh gas flow 3 L·min)
Study: 20137805
Drug: 8-week streptomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week streptomycin (15 mg/kg once daily) and oral rifampicin (10 mg/kg once daily) for 8 weeks
Study: 20137805
Drug: 4-week streptomycin
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week streptomycin (15 mg/kg once daily) and oral rifampicin (10 mg/kg once daily) for 4 weeks followed by rifampicin and clarithromycin (7.5 mg/kg once daily) for 4 weeks
Study: 17645253
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Bushen Capsules (Control Group II)
Study: 16098615
Drug: Isotonic Ems
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic Ems Mineral Salts (EMS) solution (1-2 sprays into each nostril t.d. for 14 days)
Study: 16098615
Drug: Xylometazoline solution
Normalized name: XYLOMETAZOLINE
DrugBank: Xylometazoline (DB06694)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylometazoline solution (0.05%) (1-2 sprays into each nostril t.d. for 14 days)
Study: 10449020
Drug: Hypertonic solution
Normalized name: Hypertonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic solution of lactulose
Study: 2220621
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers and enalapril
Study: 7194082
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421 (3 x 100 mg)
Study: 7194082
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421 (6 x 50 mg)
Study: 7194082
Drug: Insulin, glucagon,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin, glucagon, lactate, triglyceride concentration (Control)
Study: 7016781
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421
Study: 25431105
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure treatment (adherent patients)
Study: 25431105
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure treatment (non-users)
Study: 23420314
Drug: Iontophoresis combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis combined with local bath-PUVA therapy
Study: 23420314
Drug: Local PUVA
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local PUVA therapy
Study: 17173263
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis doses prescribed based on empirical criteria and urea kinetics model
Study: 29574980
Drug: Ramipril (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (an angiotensin-converting enzyme inhibitor)
Study: 1835959
Drug: Candoxatril (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril (200 mg) on low sodium diet (10 mmol/day)
Study: 1835959
Drug: Candoxatril (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril (200 mg) on high sodium diet (350 mmol/day)
Study: 7104144
Drug: Propranolol (0.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.18 mg/kg i.v.)
Study: 7104144
Drug: Pindolol (0.023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.023 mg/kg i.v.)
Study: 31427299
Drug: VL-2397 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: VL-2397 (3 mg to 1,200 mg single intravenous doses)
Study: 31427299
Drug: VL-2397 (300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VL-2397 (300, 600, and 1,200 mg intravenous doses every 24 hours for 7 days)
Study: 31427299
Drug: VL-2397 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: VL-2397 (single doses >30 mg)
Study: 30580349
Drug: Probiotics (lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (lactobacillus rhamnosus 35) at a dose of 0.8 mg in infants >1500 gms and 0.4 mg in infants <1500 gms in 2 ml of expressed breast milk two times daily
Study: 25603000
Drug: Amoxicillin‐clavulanate (40mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate (40mg/kg per day for 7 days)
Study: 23852661
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression and unprocessed bone marrow injection (group B)
Study: 16846090
Drug: Electrical activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical activation with 3 consecutive 40-/microsec pulses of 1.5 kV/cm direct electrical current in buffer solution
Study: 9489070
Drug: Diclofenac sustained-released
Normalized name: diclofenac Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sustained-released 75 mg tablets taken b.i.d.
Study: 9489070
Drug: Diclofenac enteric-coated
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac enteric-coated 50 mg tablets given t.i.d.
Study: 9489070
Drug: Diclofenac sustained-released
Normalized name: diclofenac Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sustained-released 75 mg tablets
Study: 9489070
Drug: Diclofenac enteric-coated
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac enteric-coated 50 mg tablets